Please ensure Javascript is enabled for purposes of website accessibility

Why Aralez Pharmaceuticals Inc. Got Slaughtered Today

By Brian Orelli, PhD - Updated Mar 13, 2017 at 3:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Fourth-quarter earnings and guidance for 2017 were not what the doctor ordered.

What happened

Aralez Pharmaceuticals (NASDAQ: ARLZ) was down 30% just before the market closed Monday after it announced disappointing fourth-quarter earnings and lackluster guidance for the year ahead.

So what

Revenue was up substantially from $6 million in the year ago quarter, to $20 million in the recently completed quarter, but that's still lower than investors were expecting given all that's happened with Aralez Pharmaceuticals over the last year. In February 2016, Pozen merged with Tribute Pharmaceuticals Canada to create Aralez Pharmaceuticals, which added about a dozen drugs from Tribute to Pozen's Yosprala as well as Vimovo and Treximet, which are marketed by its partner. Within the last year, Aralez Pharmaceuticals also acquired two other drugs, Zontivity and Toprol-XL, the latter of which included an authorized generic (AG).

Pills on top of paper money.

Image source: Getty Images.

But sales of the additions are nothing to get too excited about. Tribute added $6.4 million during the quarter; Toprol-XL, the AG of Troprol-XL, and Zontivity added $8.6 million combined, although the deal for Toprol-XL didn't close until the end of October, so it was really only two months of sales. Sales of Yosprala, which was launched in October, weren't broken out in the press release, suggesting the sales are likely pretty low.

For this year, management guided for revenue between $80 million and $100 million. The low end of that guidance is equal to the run rate coming out of the fourth quarter, suggesting there's potential minimal growth over the next year.

Now what

Management might be sandbagging, giving guidance that it knows it can hit, but if that's the case, it should have done what many companies do and just refused to give revenue guidance because the launch of Yosprala is too hard to predict.

Aralez Pharmaceuticals could be a good value at this knocked-down price, but cautious investors will want to wait until management can show that it can consistently grow revenue each quarter before investing.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.